CC-90001

• Description:

  CC-90001 is a potent, selective and orally active inhibitor of c-Jun N-terminal kinase (JNK) . CC-90001 shows 12.9-fold selectivity for JNK1 over JNK2 in a cell-based model. CC-90001 can be used for the research of idiopathic pulmonary fibrosis[1][2].

• UNSPSC:

  12352005

• Target:

  JNK

• Type:

  Reference compound

• Related Pathways:

  MAPK/ERK Pathway

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/cc-90001.html

• Concentration:

  10mM

• Purity:

  99.75

• Solubility:

  DMSO : 125 mg/mL (ultrasonic)

• Smiles:

  O=C(C1=CN=C(NC(C)(C)C)N=C1N[C@H]2C[C@@H](O)[C@H](C)CC2)N

• Molecular Formula:

  C16H27N5O2

• Molecular Weight:

  321.42

• References & Citations:

  [1]Bennett B, et, al. CC-90001, a Second Generation Jun N-Terminal Kinase (JNK) Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine 2017; 195:A5409.|[2]Kolb M, et, al. Therapeutic targets in idiopathic pulmonary fibrosis. Respir Med. 2017 Oct;131:49-57.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 2

• Isoform:

  JNK1; JNK2

• CAS Number:

  [1403859-14-2]